Russians love Putin's dustup with the West. But they've stopped spending money
Why rival discounters are vying for control of Family Dollar Stores
Twitter's head of product, Daniel Graf, must make the service more user-friendly without offending hard-core fans
Yale's Robert Shiller is sending up warning flares. It may be best to ignore him
To minimize flood chaos, turn the hospital upside down
Bayer is marketing Berocca as performance drink, but Australians know what it's really for
A group of business school researchers wants chief executives and working stiffs alike to ask themselves why they don't follow their own values
Advice for a small bed-and-breakfast trying to get on the map for international tourists
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."